Amarin Corp ADR Dossier
Qualitative Analysis
Business overview
Amarin Corporation plc is a global biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company's primary asset is its flagship product, Vascepa (icosapent ethyl), a highly purified eicosapentaenoic acid (EPA) derived from fish oil. Vascepa is approved by the FDA and EMA (under the brand name Vazkepa in Europe) as an adjunctive therapy to reduce the risk of cardiovascular events in high-risk patients with elevated triglyceride levels. Following a major legal setback in 2020 that invalidated several of its key U.S. patents, Amarin transitioned from a direct-sales-heavy model to a global expansion strategy utilizing strategic partnerships, notably licensing European commercialization rights to Recordati.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive restructuring program initiated in mid-2025 to streamline global operations, eliminate commercial roles in European operations, and transition to a fully partnered international commercial model.
Expected impact: Targeting approximately $70 million in annual operating expense savings, significantly lowering the operating cost structure and accelerating the path to positive cash flow.
Strategic focus on maintaining leading market share for the VASCEPA franchise in the United States despite generic competition, supported by regaining exclusive status with a large national pharmacy benefit manager (PBM).
Expected impact: Sustains core product revenue volumes and cash generation to fund international expansion and operations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Recordati exclusive rights to commercialize VAZKEPA (icosapent ethyl) across 59 countries, primarily in Europe, transitioning Amarin to an asset-light, fully partnered international commercial model.
Terms: Upfront cash payment of $25 million to Amarin, potential commercial milestone payments of up to $150 million contingent upon Recordati achieving predefined annual net sales levels starting from €100 million, and supply-based revenues including royalties.
Partnership to develop and commercialize VASCEPA in Mainland China, Hong Kong, Macao, and Taiwan. EddingPharm secured regulatory approval for the cardiovascular risk reduction (CVRR) indication from China's NMPA in mid-2024.
Terms: Upfront and milestone payments of up to $169 million (including a $15 million regulatory milestone earned upon CVRR approval in China) and tiered double-digit percentage royalties on net sales.
Partnership to register, commercialize, and distribute VASCEPA in Canada.
Terms: Upfront and milestone payments of up to $65 million (including a $5 million non-refundable upfront payment) and tiered double-digit royalties on net sales in Canada.
Vianex acts as the sole and exclusive distributor to import, register, distribute, and commercialize VAZKEPA in Greece following national reimbursement approval.
Terms: Amarin supplies finished product to Vianex at a defined transfer price.
Collaboration on the development and commercialization of drug products and indications based on the active pharmaceutical ingredient in VASCEPA (EPA). Amarin obtained an exclusive license to certain Mochida intellectual property to advance its interests in the U.S. and other territories.
Terms: Amarin made a non-refundable upfront payment of approximately $2.7 million in June 2018, with subsequent milestone payments (including $1.0 million in January 2020 and $1.0 million in December 2020) and royalties on net sales of future products.